SCHEMBL6824124

SCHEMBL6824124

COCCOc1c(C2=NCCN2)cc2cc(-c3ccc(C(F)(F)F)cc3)ccc2c1Cl

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 7/20 0.45
P2RY14 Q15391 1/20 0.35
CD274 Q9NZQ7 6/20 0.35
PDCD1LG2 Q9BQ51 5/20 0.35
HTR1D P28221 1/20 0.35
ADRA1A P35348 1/20 0.35
CNR1 P21554 1/20 0.34
TRPV3 Q8NET8 1/20 0.33
MALT1 Q9UDY8 1/20 0.33
PDCD1 Q15116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6820993 0.89 LMNA (0.42) NISCHCD274PDCD1LG2
SCHEMBL6820859 0.89 NISCH (0.42) NISCHCD274PDCD1LG2PDCD1
SCHEMBL6826683 0.83 NISCH (0.36) NISCHCD274PDCD1LG2PDCD1
SCHEMBL6826510 0.83 NISCH (0.52) NISCHCD274PDCD1LG2PDCD1
SCHEMBL6824657 0.83 NISCH (0.36) NISCHCD274PDCD1LG2ADRA1APDCD1
Hydrochloric Acid SCHEMBL7736762 0.81 MRGPRX4 (0.37) P2RY14CNR1MALT1
SCHEMBL6825218 0.81 KCNH2 (0.43) NISCHCD274PDCD1LG2PDCD1
Hydrochloric Acid SCHEMBL7736696 0.81 NISCH (0.46) NISCHCD274PDCD1LG2HTR1DADRA1A
Hydrochloric Acid SCHEMBL7738758 0.81 KCNH2 (0.43) NISCHCD274PDCD1LG2PDCD1
Hydrochloric Acid SCHEMBL7727584 0.80 NISCH (0.48) NISCHCD274PDCD1LG2HTR1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US claimed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP claimed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO claimed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP claimed
US-20040009976-A1 Hypoglycemic imidazoline compounds TAKEUCHI KUMIKO (US) 2004-01-15 US disclosed
EP-0924209-B1 Hypoglycemic imidazoline compounds LILLY CO ELI (US) 2003-05-02 EP disclosed
EP-1266897-A2 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 2002-12-18 EP disclosed
WO-1999032482-A1 HYPOGLYCEMIC IMIDAZOLINE COMPOUNDS ELI LILLY AND COMPANY (US) 1999-07-01 WO disclosed
EP-0924209-A1 Hypoglycemic imidazoline compounds ELI LILLY AND COMPANY (US) 1999-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009976-A1 Hypoglycemic imidazoline compounds GPR119, IAPP, GLP1R NISCH 277/4885P2RY14 1521/4885CD274 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.